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1. Introduction
Liver metastases are now detected at earlier stages because of the improvement in imaging
techniques and the closer follow-up of cancer patients. The right lobe is metastasized to more
frequently than the left, mainly due to the preference of tumour emboli circulating through
the right portal vein as a feature of the portal stream. Liver metastases may also arise from
draining lymphnodes through venolymphatics communications or the thoracic duct [1].
Lymphatic metastases may arise from these portal blood born liver metastases, usually
pointing to a very poor prognosis.
All patients with colorectal liver metastases (CLM) are classified as having stage IV disease in
the TNM classification of liver tumours given by the International Union Against Cancer
(UICC) and the American Joint Committee on Cancer (AJCC), but they form a very heteroge‐
nous group (synchronous and metachronous metastases, node-positive and node-negative
disease, unilobar and bilobar lesions, and extrahepatic or no extrahepatic disease) and their
long-term outcomes may vary widely. Several clinical scores [2-6], based on retrospective data,
have been developed to predict more accurately the prognosis of these patients and thus to
stratify their management, but their validation is still limited.
2. Colorectal liver metastases
The liver is the most frequent and often unique site of metastasis in patients with colorectal
cancer, both at the time of diagnosis (20–25% of cases) or after an apparently radical surgery
on the primary tumour (40% of cases) [7]. Less than one third of patients with CLM have disease
limited to one lobe and in only 10% of cases is metastasis solitary.
© 2013 Serrablo et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
CLM are usually asymptomatic but patients may develop abdominal discomfort, weight loss,
general malaise and hepatomegaly with advanced disease. Jaundice, ascites and occasionally
portal hypertension are late signs. Pain and fever related to necrosis and infarction of a
metastasis are usually transient symptoms.
CLM are often harder to palpate than the normal liver, extend by concentric growth and may
spread to other structures by penetrating the usually rigid Glisson´s capsule.
The natural history of metastatic colorectal cancer is variable. Median survival without
treatment is less than eight months from presentation but the prognosis is better for those
patients with isolated CLM. Survival of patients with untreated CLM at five years is unusual.
2.1. Diagnosis
Diagnosis of CLM is mainly based in imaging studies, with history, physical examination and
serum levels of alkaline phosphatase, aspartate aminotrasaminase, glutamyl transferase and
carcinoembryonic antigen playing a minor role. Accurate detection of CLM has important
prognostic implications, since untreated liver metastases have a poor prognosis (5-year
survival rate of 0-3%) while the resection with curative intent offers a much better one (5-year
survival rate from 35% to 58%) [8]. The imaging of these lesions, needed for a careful pre-
operative selection of patients, should assess their number, size and segmental location, their
differential diagnosis with benign lesions, possible hilar lymph node involvement (although
the pre-operative diagnosis is difficult), the evaluation of vascular invasion, the liver volume
(insufficient residual volume of liver parenchyma is a contraindication to surgery), and the
presence of extrahepatic disease (although peritoneal carcinomatosis is very difficult to detect.
The specificity of imaging studies detecting CLM is higher than 85%, and the sensitivity for
detection of liver metastases is progressively increasing from transabdominal ultrasound (US)
to multi-detector computed tomography (CT), magnetic resonance imaging (MRI) and
fluorodeoxyglucose-enhanced positron emission tomography (FDG PET) [9]. FDG PET and
CT can be combined to provide fused images, achieving high spatial resolution and functional
information in the same images (FDG PET/CT).
Biopsy of suspected CLM is not usually done in patients with potentially resectable disease
because imaging studies are generally accurate enough and percutaneous biopsy may be
asociated with extrahepatic dissemination.
CT scan remains the dominant imaging modality both for detection of CLM and preoperative
planning as well as for treatment monitoring and post-treatment surveillance. CT combined
with FDG PET/CT may avoid additional studies and may improve patient management
[32-34]. Contrast-enhanced MRI should be reserved for problem solving. Because MRI
sensitivity in detecting extrahepatic disease in the peritoneum and chest is low, it is not a
desirable primary imaging modality.
2.1.1. Ultrasonography
US is a rapid and non-invasive method for screening patients with suspected liver metastases.
While it is highly efficient in distinguishing patients with diffuse hepatic metastases, it is more
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operator dependent than other imaging studies and its sensitivity (50-70%) and specificity are
surpassed by other imaging methods.
Contrast-enhanced US (CEUS) improves the sensitivity compared to conventional B-mode
sonography by using microbubbles of gas that flood the blood pool after intravenous injection.
Metastases show characteristic images in arterial, portal and delayed phases, thereby increas‐
ing CEUS sensitivity and specificity in staging liver metastases and approaching those of CT
and MRI [8]. As CEUS improves the detection of metastases smaller than 1 cm and of those
lesions that are isoechoic with respect to adjacent liver parenchyma, it improves the perform‐
ance of US in around 13.7% of the cases [10]. CEUS can be suboptimal in visualizing certain
parts of the liver, especially in obese patients and/or in cases of steatosis and may find difficult
to differentiate hypervascular metastases from haemangiomas and metastases from small
cysts [11]. For these reasons, US should not be the imaging method of choice in the assessment
of CLM.
2.1.2. Computed tomography
CT sensitivity and specificity are high (70–85% and 90% respectively) especially for lesions
bigger than 1.5–2 cm. Although sensitivity is lower for small subglissonian metastases, multi-
slice CT enables detection of lesions of 0.5 cm in size (thicknesses of 2 or 4 mm are the most
effective for detection of focal liver lesions, with an identical detection rate of 96% for both)
[12]. Fast data acquisition allows bi-phasic contrast-enhanced scan during the arterial-
dominant and the portal perfusion phases after bolus contrast administration, prior to the
equilibrium phase (hepatic venous or interstitial). This part of the study should be considered
as standard for the optimised view of the complex vascularization of the liver and potential
hepatic lesions.
CT can be used for evaluating the liver lesion, liver parenchyma and hepatic vessels in the
same sitting, since its software grants 3-D data sets, which improves multiplanar imaging,
demonstrates the vascular anatomy and characterizes the lesions well. This feature, together
with improvements in bolus-tracking, facilitates CT-angiography of the liver and mesenteric
vessels, which can be invaluable in patients undergoing hepatic resection or transarterial
chemo or radio-embolisation. The CT portal venogram is useful in evaluation of the portal
system. Quantitative perfusion studies can also be done.
CT software is also able to highlight different liver segments, assess liver volume and to create
vascular maps for arterial and portal inflow and hepatic venous drainage, which are necessary
in evaluating the feasibility of major hepatectomies. A simulation of surgical resection can be
performed. This information can be shown visually using coloured maps or three-dimensional
movies [13], which are tools increasingly used because they ease surgical dissection but still
requiring validation.
The utility of CT as a pre-operative tool to evaluate CLM is inversely proportional to the time
elapsed between imaging and surgery, which may explain the conflicting reports on the
accuracy of CT [14].
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2.1.3. Magnetic resonance imaging
Although CT is usually preferred because of its availability and its good surveillance of the
extrahepatic abdominal organs and tissues, MRI has an advantage in the characterization of
focal lesions. It is also used for patients who cannot receive intravenous iodinated contrast
material or there is concerns about the risk of radiation from repeated exposure to CT. MRI
sensitivity and specificity (85-90% and up to 95% respectively) are higher than those of CT, but
this comparison needs to be reassessed periodically, owing to the rapid evolution of both
technologies.
The extracellular agent gadolinium-chelate complex is the most commonly used contrast
media in dynamic MRI. The current standard MRI liver protocol includes a T2-weighted
sequence, a T1-weighted sequence and a three-phase technique after administration of
gadolinium. Detection of CLM is maximized during the portal venous phase, like in CT scan.
Organ-specific contrast agents with hepatocyte specificity (mangafodipir trisodium
[MnDPDP], gadobenate dimeglumine [Gd-BOPTA]) or reticuloendothelial system specificity
(superparamagnetic iron oxide [SPIO] particles, captured by Kupffer cells) increase the
sensitivity and specificity [15,16], but data about their benefits are controversial and they are
generally expensive and not widely available.
Diffusion-weighted MR imaging (DWI) depict differences in molecular diffusion caused by
the random motion of molecules without the need for a contrast agent [8] and can obtain
quantitative indices, helpful in the assessment of disease response to novel therapeutics
(including antivascular and anti-angiogenic therapy) [17]. It can be a simple and sensitive
method for screening focal hepatic lesions and very useful for differential diagnosis [18].
2.1.4. Positron emission tomography
FDG PET sensitivity and specificity are high for CLM (92–100% and 85–100% respectively).
However, false negative and false positive findings in FDG PET for CLM are not negligible [19]
and its positive predictive value (PPV) is not high. Thus, some teams recommend histological
confirmation when the findings suggests non-resectability [20]. Some studies have demon‐
strated high diagnostic values of FDG PET in the evaluation of liver metastases [21-23]
confirming its superior sensitivity on a per patient basis, but not on a per lesion basis. Never‐
theless, its role is not yet clear owing to the small number of studies [24].
In the context of CLM, FDG PET/CT may avoid unnecessary surgery when it detects extrahe‐
patic foci of disease that are not depicted or characterized as malignant by other imaging
methods [25]. When these patients have a FDG PET prior to surgery, there is a lower probability
of non-therapeutic laparotomy [26] and an improved survival [27], reflecting better patient
selection. As a drawback, this technology is not suitable for liver resection planning.
2.1.5. Intraoperative ultrasonography
The best standard of reference when comparing diagnostic studies is laparotomy with
bimanual palpation and intraoperative ultrasonography (IOUS). This method finds additional
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lesions in 33% of patients with preoperative diagnosed CLM and new lesions in 5% of patients
without known CLM [1].
IOUS has higher sensitivity (98%) than transabdominal US, CT and MRI (its specificity is 95%),
allows the detection of lesions 0.5 cm in size and defines the relationship between lesion, vessels
and biliary structures. It is generally considered the gold standard for detecting liver lesions
and is regarded as a routine investigation, since it modifies the planned surgical strategy in
18-30% of the patients. In addition, Doppler and spectral Doppler facilitate the technique of
surgical resection.
Laparoscopy allows an assessment of the peritoneal spread, liver surface, extrahepatic disease
and vessel invasion. Its combination with laparoscopic ultrasound (LIOUS) modifies the initial
surgical plan in 20–30% of the cases [12].
Contrast enhanced IOUS (CEIOUS) shows some benefit over pre-operative imaging and IOUS
since it improves the ability to characterize already detected lesions and facilitate the detection
of new ones [28-31].
2.2. Surgical treatment
2.2.1. Resectable CLM
Hepatic resection offers the only chance of long-term survival for patients with CLM, the first
large series concluding that there was a benefit for surgery in selected patients with CLM being
reported in 1978 [35]. The 5-year survival rate for these patients has increased from about 30%
two decades ago to nearly 60% nowadays, with a 10-year overall survival of 20–25% for
radically resected patients [36].
Criteria for resectability
The resectability rate has improved thanks to pre-operative imaging techniques, patient
selection, surgical techniques, postoperative care and new cytotoxic and biologic agents for
preoperative and post-operative treatment. Thereby, the criteria for resectability of these cases
have changed dramatically. The number of lesions (1 to 3 unilobar metastases), the size of the
lesion (less than 5 cm), the interval of time (preferably presenting at least 12 months after
resection of the primary tumour), the minimum margin of 1 cm in width and the absence of
hilar adenopathy or extrahepatic disease, are no longer considered as determinant factors
when considering resectability.
The number of metastases is not a risk factor for long-term survival providing that a R0
resection (complete resection with no microscopic residual tumour) has been achieved [37].
Some studies have shown that the degree of response to chemotherapy is a stronger predictor
factor for longterm survival than the number of metastasis. Although reports have been
conflicting, evidence shows that size is not a resectability factor, but a factor related to tumour
aggressiveness. Likewise, the width of the surgical margin has no effect on survival whenever
the margin is microscopically negative [38-40], though resection planning should aim for an
optimum margin, i.e. greater than one centimeter in width. Extrahepatic disease was consid‐
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ered a contraindication to liver resection until few years ago. Five-year survival rates of 12%
to 37% after hepatic resection in selected patients, independent of the location of the extrahe‐
patic disease (lung, primary colorectal recurrence, retroperitoneal or hepatic pedicle lymph
nodes, peritoneal carcinomatosis, miscellaneous) have been reported [41-45]. In most of the
patients, peritoneal disease is regarded as a contraindication to hepatic resection, but can be
considered in cases of stable or chemo-responsive disease when an R0 resection is achievable.
These patients should be classified as having borderline resectability [46]. Positive hilar lymph
nodes have been associated with a poor survival and are also generally considered as a
contraindication to liver resection of CLM. Again, however, some studies have shown lengthy
survival in some patients, particularly if involved nodes are limited to the hepatoduodenal-
retropancreatic area [47,48], although this nodes are not routinely removed.
In short, only two criteria for resectability are universally meaningful: (1) It must be possible
to remove all disease with a negative margin; (2) There must be adequate remaining hepatic
reserve. The only traditional prognostic indicator of recurrence that precludes long-term
survival is a positive resection margin [34].
Accordingly, CLM are considered as resectable when they can be completely resected, two
adjacent liver segments can be spared while sustaining an adequate vascular inflow and
outflow and biliary drainage,  and the volume of  the future liver  remnant (FLR) is  ade‐
quate (at least 20% of the total estimated volume for liver with normal parenchyma, 30–
60% for liver with chemotherapy, steatosis or hepatitis, 40–70% for liver with cirrhosis) [46].
To assess resectability clinically it is useful to estimate FLR to body weight ratio, which should
be greater than 0.5. However, there is no universaly adopted guideline for “resectability” of
primary or metastatic liver cancer and often the experience of the individual surgeon plays
an essential role.
Chemotherapy
Optimal regimens and timing of chemotherapies when liver resection is possible are unclear.
The efficacy of the peri-operative chemotherapy on survival for resectable liver metastases has
not been justified. Some authors suggest that treatment of resectable CLM, in the absence of
high-risk features, should begin with surgery and then consider adjuvant chemotherapy [2].
There is no evidence to support neoadjuvant chemotherapy in patients with resectable disease
[49]. Moreover, since around 7% of tumours will progress while on chemotherapy, this
approach may compromise a few patient’s chance of cure if routinely used. If high-risk features
are present, most physicians prefer a short course of systemic pre-operative chemotherapy.
Patients with a perforated tumour or a considerable lymphatic burden are considered
candidates for neoadjuvant chemotherapy before liver surgery. The EORTC 40983 study
evaluated peri-operative chemotherapy vs. surgery alone in resectable hepatic metastases and
did not demonstrate a clear advantage of preoperative chemotherapy in patients with
resectable CLM. Neither could this study determine if neoadjuvant, adjuvant or peri-operative
chemotherapy was superior. In this trial, the postoperative complication rate was significantly
increased in those patients who received perioperative chemotherapy versus surgery alone.
Some of these complications were biliary fistula, hepatic failure, intra-abdominal infection,
and the need for re-operation. Supporters of peri-operative treatment point out that surgery
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is facilitated and that the treatment provides information on tumour biology. The same study
demonstrated that no patient progressed to an unresectable condition, that short cycles of
treatment provided minimal liver toxicity and that survival improved in the chemotherapy
sub-group [50]. Livers affected by chemotherapy are usually more rigid, more difficult to
manage and tend to bleed more easily at surgery. Moreover, questions about the management
of “ghost lesions” after complete response, that cannot be detected with IOUS, remain
unanswered.
When resection is considered appropriate, it is imperative to have a high quality abdominopel‐
vic CT (or MRI) within a month of the date of surgery. A chest CT should be done at that time.
Resection
Detailed knowledge of liver anatomy, inflow and outflow control, low central venous pressure,
IOUS, ultrasonic dissection, argon beam coagulation, etc. contribute to reduce blood loss
during the resection of CLM. Intraoperative bleeding is the main cause of postoperative
morbidity and mortality since blood transfusion is associated to a decreased long-term
survival, an increased perioperative mortality, a higher complication rate, a longer hospital
stay, and an increased risk of infectious complications [51].
Hepatic segmentectomy, based on Couinaud segments, is preferable for localize lesions; a non-
segmental resection may be technically more difficult and compromise the vascularity of
adjacent residual liver. Nevertheless, IOUS must be used before attempting a wedge resection
of an apparently superficial nodule. For larger or multiple CLM, standard anatomical resec‐
tions must be employed. Additionally, the Brisbane 2000 Terminology of Liver Anatomy and
Resections is recommended to avoid confusion in the terms used when describing surgical
techniques [52].
The inability to obtain a free surgical margin during liver resection for CLM should not be a
contraindication to surgery, provided complete macroscopic removal of all metastatic lesions
is achieved (positive margins or R1 resection), since survival is similar to that of R0 resection,
despite a higher recurrence rate (5-year and 10-year overall survival rates are 61% and 43% in
R0 vs. 57% and 37% in the R1) [53].
Laparoscopic liver resection are now more frequently performed since the first one reported
in 1992 [54]. It shows advantages in the short term over open surgery but there are still no data
to indicate the impact of this procedure on long term outcome.
Mortality is less than 5% and morbidity is around 30%, given the wide variations in surgical
aggressiveness. Postoperative hepatic failure can be a lethal complication. This depends on the
volume and the function of the residual liver. In general, the larger the hepatic resection the
greater the probability of postoperative complications. Other complications that may contrib‐
ute to or be related to postoperative liver failure include haemorrhage, bile leak, intra-
abdominal sepsis, and cardiopulmonary dysfunction.
In regard to surgery of synchronous and metachronous CLM, simultaneous colon and liver
resection has been shown to be safe and efficient, since prognosis is not dependent on the time
of resection of CLM.
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2.2.2. Initially non-resectable CLM
Some techniques may be used when CLM are not at first resectable because of an insufficient
FLR. Strategies to increase the volume of the hepatic remnant include conversion chemother‐
apy, portal vein occlusion, staged liver resection and combination of these procedures. Also,
ablative techniques may be considered alone or in conjunction with resection.
Chemotherapy
Chemotherapy leads to improved survival in patients with unresectable CLM. In these cases,
upfront chemotherapy in asymptomatic patients compared with resection of the primary
tumour does not seem to affect survival significantly. However, without liver resection 60%
of the patients are alive after 2 years so that resection of the primary lesion for palliative reasons
and local control is recommended in rectal cancer [55].
The goal of conversion chemotherapy is downsizing the tumour for re-considering its
resection. New chemotherapeutic regimens combining 5-FU, folinic acid and oxaliplatin
(FOLFOX) and/or irinotecan (FOLFIRI) have improved response rates (approximately 50%),
enabling 10-30% of the patients with initially unresectable disease to be operated [56]. Com‐
bined with biologic agents that target angiogenesis (bevacizumab) and the epidermal growth
factor receptor (EGFR) in K-ras wildtype tumours (cetuximab), response rates of up to 70% are
achieved [34]. A new re-evaluation for resection should be done after 2 or 3 months of pre-
operative chemotherapy and every 2 months thereafter. Hepatic arterial infusion (HAI) of
chemotherapy may be added to systemic therapy, obtaining a higher concentration of drugs
in the liver with less systemic toxicity. Although response rates are higher than systemic
chemotherapy, survival does not change so far. Furthermore, its complication rates are so high
(57%) that it is discarded as a first option.
Chemotherapy should be stopped when the CLM have been downsized to the point where
hepatic resection is possible in order to reduce liver toxicity and to avoid a complete clinical
response. A complete response on CT scan does not mean cure since in over 80% of the cases
there are viable cancer cells in the initial site of the metastasis [57]. These ghost lesions have to
be removed or ablated, considering the FLR [58-60].
Tumour progression is associated with a poor outcome, even after potentially curative
hepatectomy. Therefore, tumour control before surgery is crucial to offer a chance of prolonged
remission in patients with multiple metastases [56]. Only 50% of tumours can be expected to
show a partial response to chemotherapy. Patients deemed to be resectable during systemic
treatment should be considered as surgical candidates regardless of the associated adverse
predictive factors.
Peri-operative complications, including hepatobiliary complications, are more frequent with
lengthy pre-operative chemotherapy, probably related to the prolonged and sequential use of
multiple regimens [61]. Adjuvant treatment, usually FOLFOX, may be used following surgery,
but HAI combined with systemic chemotherapy is also an option. Trials examining the role of
adjuvant chemotherapy are difficult to conduct because of the rapidly changing chemotherapy
regimens and drugs [62]. Since post-operative morbidity affects long-term survival [63], length
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of chemotherapy treatment must be taken into account. In recent years more and more patients
with stable long-term disease (more than 20 months) are considered for surgical treatment.
Portal vein occlusion
When the FLR is insufficient portal vein occlusion should be considered. In 1990 Makuuchi
presented the portal vein embolization (PVE) of the right portal branch to induce hypertrophy
of the left side of the liver, enabling a safer removal of large or multiple tumours, mostly located
in the right hemiliver and segment IV [64]. The rationale behind this approach is to induce
atrophy of the tumour-bearing lobe with subsequent hypertrophy in the contralateral lobe by
diverting the portal venous flow into the liver section that is expected to remain. In general,
two methods of portal vein occlusion can be employed: PVE or surgical portal vein ligation
(PVL). Neither technique has clear advantage.
Portal occlusion increases the FLR between 10% to 46% within 2 to 8 weeks and enables a R0-
resection in 70% to 100% of selected cases. However, some patients show tumour progression
after PVE, but it is not clear whether this is just a matter of time (from portal vein occlusion to
operation) or is due to growth stimuli to the tumour by the induced liver regeneration. Portal
vein occlusion also constitutes a dynamic pre-operative test on the capacity of the liver to
respond to the surgical aggression: If a hypertrophy greater than 5% is achieved, there is a low
risk of a severe post-operative liver insufficiency [65].
The concomitant administration of chemotherapy may decrease both the tumour load and the
post-operative recurrences. Chemotherapy does not seem to affect the hypertrophy induced
by PVE. A few studies using bevazucimab recommend a 6 week waiting period before surgery,
although its influence on the hypertrophy is unclear.
Percutaneous PVE is usually well tolerated with minimum side effects such as fever, nausea,
and transient abnormality of liver function test, and with a complication rate below 5% [66].
Major liver surgery after PVE has a complication rate of 1% for the PVE itself and a complication
rate of 8.8% for the subsequent resection [67]. It increases the feasibility of liver resection by
19%. The actuarial survival rate after surgery is 40% at 5 years, similar to that of patients
resected without PVE [68].
Two-stage hepatectomy
It is the combination of two sequential and planned liver resections when it is impossible to
resect all liver metastases in a single procedure, while preserving at least 30% of functional
liver volume to avoid post-operative liver failure. The first surgery attempts to resect the
majority of CLM and to get hypertrophy of the remnant liver. The technique should be planned
well in advance to achieve complete removal, admitting that around 30% of patients will not
be rescued on the second hepatectomy.
Usually, on the first hepatectomy the FLR is cleared out of tumours with non-anatomic
resections and/or radiofrequency ablation or at most a single segment resection [69]. This first
stage can also be performed together with laparoscopic or open colorectal resection. After a
period of recovery of 4 to 6 weeks and subsequent hypertrophy of the tumour-free lobe, tumour
removal is completed by resection of the larger tumour mass in the contralateral liver lobe.
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The majority of patients in whom this approach failed, did so because they had developed
disease progression in the meantime.
As another option, two to four weeks after the first stage PVE may be performed [70]. The
second surgery can be done on the fourth or fifth week after PVE, when a CT confirms that an
adequate hypertrophy of the non-embolized hemi-liver is achieved. Alternatively, portal vein
occlusion can be done during the first hepatectomy through the ligation and alcoholization of
the right portal vein, which is the side more often embolized [71,72]. This modification is based
on evidence that PVL triggers a similar or better regenerative response than PVE and could be
safely applied, even in combination with partial hepatectomies of the left hemiliver.
In contemporary series of two-stage resection after PVE, 69% to 72% of the patients completed
the second stage, the most common reason for dropout being tumour progression. Chemo‐
therapy responsive patients who completed the resection have a 5-year survival rate of
32%-51% [73,74]. If new CLM or extrahepatic lesions are found, such as localized peritoneum
implants, resection can still be performed if a R0 resection can be achieved. Pre-operative
chemotherapy may be administered during the entire process.
Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS)
This technique has been recently described [75] It is a new concept of two-staged extended
right hepatectomy with initial surgical exploration, right PVL, and in situ splitting (ISS) along
the right side of the falciform ligament to induce rapid hypertrophy of the left lateral lobe in
patients with marginally resectable or primarily nonresectable primary and metastatic liver
tumours.
The selective embolization or ligation of segment IV portal branches when an extended right
hepatectomy is planned has a significant impact on the hypertrophy of the FLR. However, the
completeness of segment IV branch embolization requires optimal access and may frequently
be incomplete. Combining PVL with ISS by nearly total parenchymal dissection induce a
median hypertrophy of 74% (above that achieved by PVL or PVE alone) after a median time
interval of 9 days.
This short time interval of about one week for hypertrophy overrides the risk of tumour
progression in the meantime. Although for some patients the ALPPS can be the only chance
to allow resection at all, further research needs to be conducted about short- and long-term
results, such as accelerated development of micrometastases on the future remnant liver,
systemic stress responses affecting the second step of resection, and survival and progression
patterns [76]. In order to address the oncologic benefit of this new approach a registry has been
created [77].
Laparoscopiy has also been used in this technique, showing that it is feasible and may be
worthwhile in experienced hands [78,79].
Some authors have highlighted possible drawbacks of ALPPS such an increased morbidity
and mortality rates in the first reported series [80], the presence a devascularized, necrotic
segment 4 in patients who could not be candidates for second stage because of insuficient
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hypertrophy [81] and scarce advantages over the previous techniques [82], recommending to
reserve ALPPS for cases of unexpected tumour extension [83].
Technical advantages of ALPPS include an easier second procedure (the rapid hypertrophy of
the remnant liver enables the second surgery before the development of adhesions), a faster
recovery for the patient, with the possibility of restoring chemotherapy earlier, and the
performance of the colorectal resection simultaneously with the first step of the procedure,
including the tumour cleaning of the FLR (thus minimizing the risk of complications associated
with postoperative liver failure) [84]. Of course, refinement in technical aspects and optimized
patient selection for this procedure is needed (Figure 1).
Figure 1. First stage of ALPPS




The precise role of ablative therapy is yet to be established. It can be used in patients with
associated comorbidity that precludes resection and in patients who decline surgery, although
there are significant risks associated with the procedure. Also patients with treatable extrahe‐
patic disease or whose tumours have been downsized by chemotherapy but are not resectable
may be considered for ablative therapy.
In radiofrequency ablation (RFA) a needle is placed into the centre of the metastasis. Alter‐
nating current results in frictional heat, which can reach up to 100°C, causing coagulative
necrosis and irreversible tissue injury. The ablation zone varies in shape and size. Vessels
situated next to the ablated tissue interfere with the ablative techniques by the “heat sink
effect”. Minor complications occur in 2.4 to 12% of patients; major complications appear in up
to 5.6%; mortality rate is approximately 0.5% [85]. RFA treatment can achieve a 3-year survival
rate of 25%. The combination of RFA and systemic chemotherapy has been shown to achieve
a 5-year survival rate of 30% [86-88].
Laser-induced thermotherapy (LITT) consists in the local administration of laser light deliv‐
ered to the tumour by means of fibers of quartz crystal. The heating effect destroys tissue.
Morbidity and mortality are similar to RFA. Local tumour control at 6 months is achieved in
approximately 97% of the patients [85].
For microwave ablation (MWA), microwaves are used to agitate water molecules in the tissue
and produce frictional heat which leads to large volumes of coagulative necrosis. Transmission
is not limited by tissue desiccation and charring as in RFA, allowing higher intratumoural
temperatures, a larger ablation zone, shorter treatment time, and more complete tumour
killing. Five-year survival rates of 32% have been reported.
High-intensity focused ultrasound (HIFU) is an innovative technique for the extracorporeal
treatment of different tumour masses. Treatment is administered with a lens-focused trans‐
ducer that elevates the tissue temperature to 60°C. In addition, the mechanical effects of the
highintensity ultrasound assist the destruction of the tumour cells. Adverse effects seems to
be minor [89].
Cryotherapy uses liquid nitrogen or argon to cool tumour tissue down to -180°C. The formation
of intracellular ice crystals leads to a mechanical destruction of the interstitium. Cells on the
borderline of the ablation zone are destroyed by dehydration and occlusion of small vessels.
Repeating cycles of freezing and thawing are used to ensure irreversible cell damage. Com‐
plications are reported in approximately 30% of all cases. Mortality rates between 1.5% and
4%. An “ice-cracking” of the liver tissue is seen in 5 to 28% of the patients receiving the
treatment. Five-year and 10-year survival rate of 44% and 19% are reported, respectively [90].
The increased local recurrence rates and the high complication rates have led to a diminishing
use of this technique.
2.2.3. Total vascular exclusion: In-situ, ante-situ and ex-situ procedures
Techniques learned in liver transplantation, reduced adult-sized liver for children, living
related donor liver transplantation and split liver transplantation are useful in liver resection.
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Some tumours deemed unresectable with standard techniques can be resected using in-situ,
ante-situ and ex-vivo or bench liver surgery.
The common basis for these techniques is the total vascular exclusion (TVE) of the liver and
the perfusion of the organ by preservation hypothermic solution. The techniques differ in the
extent to which liver is mobilized from its vascular connections, hilum and caval vein. Usually,
veno-venous bypass is used to avoid venous congestion during prolonged caval and portal
crossclamping and a hypothermic preservation solution is instilled through the portal vein.
Hypothermic perfusion leads to a better tolerance to ischemia [91]. Wrapping of the liver with
ice-cold towels is recommended to optimize the effect of cold preservation.
The main indications of the three techniques are tumours that involve vascular structures of
the hylum, venous confluence or inferior vena cava (IVC), or are in close proximity to them.
The technique to use depends on the tumour location and its relationship with the three hepatic
veins and caval vein. In the ante-situ procedure the division of the suprahepatic vena cava
allows rotation of the liver around the coronary axis, providing optimal exposition of the
venous confluence and the retrohepatic vena cava. In the ex-situ technique the liver is
completely removed from the patient and perfused with preservation solution, allowing
complex reconstructions of hepatic veins or portal structures after which the liver is reim‐
planted. Since the first description by Pichlmayr in 1988, the technique has been sparingly
applied in selected patients [92,93] due to its high morbidity and mortality.
The involvement of the IVC does not necessarily preclude resection since it can be resected
and reconstructed with an autogenous vein graft or a prosthetic material. Morbidity and
mortality rates (40% and 4.5-25%, respectively) appears to be balanced by the possible benefits,
particularly when the lack of alternative approaches is considered [94].
2.2.4. Re-resection: Repeat hepatectomy
Recurrence  may occur  in  up to  75% of  CLM resected patients.  About  70% of  them are
observed within the first 12 months after resection and 92% appear within 24 months [95].
Fifty  percent  of  these  relapses  are  in  the  liver  [96]  but  only  5-27%  of  the  patients  are
candidates for potentially curative repeated hepatectomy. Repeat hepatectomy is a safe and
effective procedure under the same criteria of selection of the first hepatectomy. Although
the prognostic variables provide rough indicators of prognosis, they should not be used as
absolute contraindications to surgery. Each case needs a particular and specific evaluation:
disease-free  interval,  number  of  metastases,  quality  of  life,  general  health  condition,
resectable extrahepatic disease, assessment of residual liver volume, etc. by the multidisci‐
plinary team.
Recurrence after repeat hepatectomy has been reported in 60–80% of patients [97]. Some
patients have resectable disease limited to the liver and may be candidates for a third or even
fourth hepatic resection.
Between 9% and 30% of patients with a second hepatectomy for CLM have a third resection
[2,98-100] and around 4% of them have a fourth resection [101].
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The safety of multiple repeated hepatic resections has been demonstrated, with a low mortality
rate (0%-2%) and a morbidity rate of 5%-30%, not significantly different from those who have
had only one or two liver resections. LiverMet Survey published the largest series (n = 251) of
third hepatectomies for recurrent CLM showing a survival benefit of 29% at 5 years. Techni‐
cally, re-hepatectomies are more difficult than the first procedure because of dense adhesions
and because the liver parenchyma may be more fibrotic or friable.
3. Non-colorectal liver metastases
Pancreas, breast, ovary, rectum and stomach are the following sources of liver metastasis after
those of colonic origin in decreasing order of frequency [102]. Liver metastases from colorectal
cancer have a less aggressive clinical and biological behavior than those from others solid
tumours, like breast or lung, in which the liver is another site of systemic disease [103].
3.1. Liver metastases for neuroendocrine tumours
Gastrointestinal neuroendocrine tumours (NETs) are a diverse group of tumours that origi‐
nate throughout the gastrointestinal tract and are characterized by a relative slow growth rate
and the potential to produce and secret a variety of hormones. NETs can be classified into carcinoid
and pancreatic histological subtypes. NETs of pancreatic origin can be non-functioning or can
produce hormonally active substances: insulin, gastrin, vasoactive intestinal peptide. Carci‐
noid tumours arise commonly in the midgut and may secret serotonin and other bioactive amines.
Most of NETs will have diseminated disease at the time of diagnosis, with a 5-year survival
between 50% and 80%. The liver is the most common organ involved, followed by bone
and  lung  [104].  Almost  10%  of  all  liver  metastases  are  neuroendocrine  in  origin.  The
presence of liver metastases of NETs (LMNETs) is a distinguishing feature of malignant
neuroendocrine tumours and is the rate-limiting step for patient’s survival [105]. LMNETs
occur in 50% to 75% of small-bowel carcinoids, in 5% to 70% of foregut carinoids and about
14% of hindgut carcinoids. Furthermore, in many patients the liver remains the only site
of  metastatic  disease  for  a  prolonged  period  of  time.  Usually  LMNETs  are  multifocal,
bilobar and in more than half of the cases involve more than 50% of the liver parenchy‐
ma [106]. In spite of it, Hodul et al concluded that hepatic resection resulted in an almost
double  5-year  survival  rate  compared with  the  non-resected  group (47-82% vs.  30-40%,
respectively) [107].
Management of LMNETs is challenging, since there is not a firm consensus on the optimal
treatment strategy, except the Steimueller’s guidelines [108,109] (Table 1).
Several studies have shown 5-year survival rates of up to 85% in R0 resection for both primary
and secondary sites (Table 2). Cytoreduction is usefull as a palliative approach but it needs to
reache at least 90% of tumour volume reduction to improve both survival and symptoms [110].
Table 2: Liver resection for neuroendocrine liver metastases
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Authors Year # of patients Resolution of symptoms (%) Survival (%)
Sarmiento et al [110] 2003 170 96 75 at 3 years; 61 at 5
years
Knox et al [111] 2003 13 82 85 at 5 years
Touzios et al [106] 2005 19 95 72 at 5 years
Musunuru et [112] 2006 13 100 83 at 3 years
Table 2. Liver resection for neuroendocrine liver metastases
After surgery, the normalization of tumour markers, 5-hydroxyindoleacetic acid (5-HIAA) and
chromogranin A predict a complete resection. This last marker is more sensitive than 5-HIAA
to diagnose progression or recurrence.
RFA has been used as the sole method to achieve relief  of  symptoms and local  control.
Although this goal is attained in 60% to 80% of cases of LMNETs, a sustained response rate
is low.
TACE is contraindicated when the tumour size exceeds 50% of the liver due to the risk of liver
failure. The duration of response is short and here is also a risk of causing carcinoid tumour
lysis syndrome or crises.
Several authors advocate liver and multivisceral transplant in unresectable LMNETs, but the
role of liver transplantation in patients with LMNETs remains controversial, especially given
the shortage of donors. Less than 1% of all liver transplants have been performed for LMNETs
and, outside of a few small studies, survival does not seem to have improved. Frilling et al
1. LMNET without extrahepatic disease:
a Preferred treatment: surgical resection of both primary and all liver metastasis ± local ablative techniques
(may be one or two-step procedure)
b Treatment if unresectable disease or poor surgical candidate: continued biotherapy, hepatic artery
chemoembolization (TACE) or embolization and RFA
c Liver transplantation considered in rare cases (less than 1%)
2. LMNET with extrahepatic disease:
a Preferred treatment: biotherapy or other systemic nonsurgical treatment
b Palliative treatment if symptoms progress:
- If small number of isolated liver metastases less than 3-4 cm: RFA, TACE or embolization; may consider
minor or anatomic resection in selected cases
- If complex pattern or liver metastases: RFA, or embolization; may consider major liver resection
together with RFA for selected cases
- If diffuse pattern of liver metastases: TACE or embolization
Table 1. Consensus guidelines for the treatment of liver metastases from endocrine tumours:
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suggested a set of criteria for transplantation of patients with LMNETs: age younger than
65, primary tumour under control, absence of extrahepatic disease proven over a 6-month
period, progression of liver tumours and excessive hormonal symptoms refractory to medical
therapy [113].
An aggressive surgical approach using multi.modality therapy (resection, embolization and
RFA) leads to long-term survival in these patients. Although long-term cure can only be
achieved in a small proportion of patients with malignant NETs, significant long-term
palliation can be achieved. This aggressive surgical approach can be recommended, keeping
in mind that additional liver-directed procedures may be required or combined with surgery
to achieve effectiveness for a good quality of life.
3.2. Non-colorectal non-neuroendocrine liver metastases
Despite the established agreement on the advantage of liver resection for metastatic colorectal
and neuroendocrine tumours, the role of hepatic surgery in patients with liver metastases from
non-colorectal non-neuroendocrine (NCRNNE) carcinoma is not well defined. However, the
results reported in a number of recent studies support a developing trend toward surgery in
this setting.
There are many reasons for this lack of clear-sightedness. Because of these ununiformed
characteristics, the conclusions are that prognostic factors for liver metastases from NCRNNE
remain uncertain. These is due to many reports include neuroendocrine tumour patients in
their analysis and consequently alter survival data. In fact, most series are not comparable in
terms of mid- and long-term (tumour-free) survival, as they include patients with NCRNNE
hepatic metastases from different primary malignancies, different frequency of isolated
hepatic metastases and different tumoural behaviour, different sensitivity to chemotherapy
and different length of disease-free interval between the resection of the primary tumour and
the diagnosis of the liver metastases. In addition, to influence the variability of the series, many
studies include recruitment periods of 10 years or more so the chemotherapy regime has been
changed a lot and the results should be taken with caution.
In recent years, despite the poor results, liver resection for metastases suitable for surgery have
been carried out. The main reasons for this attitude have been above-mentioned. Also, there
are no data that actually suggest the usefulness of alternative treatments for NCRNNE liver
metastases, so this reinforces the role of surgery.
The aggressive policy used by some surgeons and oncologists, in relation to metastases
confined to the liver, should be moderated considering generic variables, such as disease-free
interval from the primary tumour. Twelve months is considered as the generic minimum
period between primary tumour and secondary disease to give an indication for surgery for
liver metastases. After this first year, any further time interval should be considered as a
progressively increasing positive prognostic factor. A longer disease-free interval is believed
to indicate less aggressive tumour biology or less account of tumoural stem-cells [103]. In a
retrospective study of 1452 patients treated at 41 centres, Adam et al demonstrated that liver
resection for NCRNNE hepatic metastases is safe and effective (Table 3). The authors catego‐
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rized the outcome according to the primary tumour and the 5-year survival after liver resection
into: favorable (adrenal, testicular, ovarian, small bowel, ampullary, breast, renal, and uterine
tumours); intermediate (gastric adenocarcinoma, exocrine pancreas, cutaneous melanoma,
choroidal melanoma, and duodenal tumours); and poor (gastroesophageal junction, pulmo‐
nary, esophageal, and head and neck tumours) [114].
Author Years # of patients 5 years survival
Harrison LE 1997 [116] 1980-1995 96 37%
Hemming AW 2000 [117] 1978-1998 37 45%
Laurent C 2001 [118] 1980-1997 39 35%
Yamada H 2001 [119] 1990-1995 33 12.1%
Takada Y 2001 [120] 1987-1999 14 NR
Karavias DD 2002 [121] 1994-2001 18 NR
Weitz J 2005 [122] 1981-2002 141 57%*
Ercolani G 2005 [123] NS 142 34.3%
Adam R 2006 [114] 1983-2004 1452 36%
Table 3. Studies with NCNNE liver metastases resection
The role of liver resection for NCRNNE liver metastases is still a matter of discussion because
only  small  studies  have  been carried  out  in  this  field  and the  conclusive  outcomes  are
collective and not specific for each type of tumour. In a comparative analysis, Reddy et al
studied the results of liver resection for metastatic tumours in 360 consecutive patients (245
colorectal and 33 neuroendocrine versus 82 NCRNNE primaries). There were no difference
in median overall survival between patients with metastases from colorectal and noncolorec‐
tal disease. The long-term outcome after resection of NCRNNE was nearly equivalent to that
of colorectal tumours [115].
3.2.1. Gastrointestinal stromal tumours liver metastases
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of
the gastrointestinal tract and account for 1%-3% of all gastrointestinal malignancies [124]. It is
thought that these tumours differentiate from intestinal pacemaker cells, also known as
interstitial cells of Cajal [125,126]. They affect mostly males between the ages of 50 and 70, and
are usually found incidentally at early stages. Large or advanced lesions may present with a
variety of clinical findings, including bleeding, abdominal pain, early satiety, bowel obstruc‐
tion or perforation.
The only definitive treatment for GIST is surgical resection. These tumours demonstrate a
broad spectrum of biological behaviours, from indolent to rapidly progressive malignancies
[127]. The liver is known to be a common metastatic site for GIST and previous studies have
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reported that 55%-72% of patients develop hepatic metastasis following complete resection of
the primary tumour [128]. Previously described treatment modalities for hepatic metastases
from GIST include anthracycline and ifosfamide-based chemotherapy regimes, TACE, surgical
resection and hepatic transplantation. However, high recurrence rates and poor survival
outcomes following hepatic transplantation have been reported. Radical surgical resection,
including hepatectomy, is the only potential treatment modality for this clinical condition.
Liver resection itself has been shown to prolong survival; this seems especially true for patients
with small metastasis and a long disease-free interval. A time to metastasis of 2 years has
actually been an independent predictor of outcome in a large group of patients with a median
survival of 61 months [129].
Imatinib mesylate (Glivec®), a selective inhibitor of tyrosine kinase, has revolutionized the
management of this disease in recent years. Imatinib has a significant shrinking effect on GIST
and can be used when primary GIST have attained a very large size or are in unfavorable
locations, increasing the risk of positive resection margins [125]. Imatinib has also become the
first line of treatment for recurrent and/or metastatic GIST. Before the advent of tyrosine kinase
inhibitors (TKIs), surgical resection was the primary treatment for hepatic gastrointestinal
stromal tumour (GIST) metastases. Although TKIs have improved survival in the metastatic
setting, outcomes after multimodal therapy comprised of hepatectomy and TKIs for GIST are
unknown. A recent report concludes that combination therapy for GIST liver metastases
comprised of surgical resection and TKIs therapy is more effective than surgery or TKIs
therapy alone [130]. There are significant prognostic implications in GIST cases with hepatic
metastasis. Recent studies have shown an overall median survival time of 39 (33-40) months
following surgery. Resection of GIST liver metastases may be curative when the primary
disease has been eradicated and negative surgical resection margins are attained (Table 4).
Author Years # of patients Median survival
(months)
Recurrence (months)
Ng [131] 1957–1987 5 33 Not recorded
Chen et al. [132] 1984–1995 6 39 3 (50%)
Lang et al. [133] 1983–1996 18 40 9 (60%)
DeMatteo et al. [128] 1982–1998 56 39 47 (84%)
[134]l. 1989–2001 10 39 7 (70%)
[135] 1984–2003 18 36 14 (77%)
Gomez et al. [127] 1993– 2005 12 43 8 (73%)
Table 4. Surgical resection for hepatic metastases from GIST, sarcomas and leiomyosarcomas
Surgical resection with curative intent for hepatic metastases from GIST should be considered
when feasible, as it may improve survival outcomes in selected patients. Recurrence of disease
can be managed with further surgery, RFA, imatinib mesylate therapy or a combination of
these treatment modalities.
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3.2.2. Liver Metastases from Breast Cancer (LMBC)
Patients with visceral metastases from breast cancer have an unlucky prognosis. Liver
metastases are infrequent as the sole site of systemic disease and even rarer as a solitary
metastasis. Only 3% to 11% of the patients have the liver as the single involved organ out of
65% of breast cancer patients with liver metastases as part of the disseminated disease [136].
Although systemic treatment can achieve response in around 60% of patients, long-term
survival is unusual, varying from 1 to 15 months [137]. Moreover, around 70% of these liver
metastases are negative for hormonal receptors so that chemotherapy is usually the only
treatment.
Extrahepatic disease has been considered as a contraindication for liver resection in these
patients, but some reports have not found differences in survival between operated patients
with or without extrahepatic breast cancer metastases, bearing in mind that most of the these
extrahepatic lesions were bone metastases treated with chemotherapy and radiotherapy
previously to surgery [138]. This retrospective study of 454 patients operated on for metastatic
breast cancer reported that 41 and 21% of these patients remain alive at 5 and 10 years,
respectively.
Few series of liver resection have been published [139,140], describing around 250 patients
operated in a few highly specialized centers (Table 5).
Autor N SolitaryMetastasis 5 years Survival Rate Pronostic factors
Sakamoto et al (2005) [141] 34 19/34 21 extrahepatic diseases
Carlini et al (2002) [142] 17 15/17 46
Yoshimoto et al (2000)[143] 25 14/25 27 "/> 1 year
Selzner et al (2000) [144] 17 22 "/> 4 years
Pocard et al (2001)[145] 65 44/65 46 N0
Seifert et al (1999)[136] 15 53(3 years) R0
Raab et al (1996)[146] 34 21/35 18 Local Recurrence
Scheuerlein et al (1998)[147] 21 9 of 21 60(2 years) R0
Table 5. Liver resection from breast cancer
These differences among series in outcome following hepatic resection may merely reflect
difference in selection criteria and in tumour biology. Resection criteria for liver metastases
from breast cancer are not yet clearly defined and a number of questions remain to be an‐
swered: Must hepatectomy be done in patients with extrahepatic disease? Which chemother‐
apy regimens must be given before and after surgery? Which is the best timing for liver
surgery?
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Eighty percent of the liver metastases were due to primary tumours less than 5 cm in size and
the number of patients with a solitary metastasis varied from 41% to 79%. The lapse of time
between breast surgery and diagnosis of the liver lesions was 21 to 60 months [140,145].
Reponse to chemotherapy appears to be an important predictor of survival following hepatic
resection for liver metastases from breast cancer. In the Adam paper, patients who remained
stable or progressed on prehepatectomy chemotherapy were 3.5 times more likely to die than
responders. Indeed, preoperative chemotherapy is a modality to prolong survival and the
response can be considered as a selection criteria.
Two pronostic factors have been identified by several authors [145]: prolonged tumour-free
interval (1-2 years) between breast cancer surgery and liver metastases diagnosis and no lymph
node involvement at the time of breast cancer. Liver surgery should be offered to every patient
with a good performance status, with predictable R0 resection and with a long disease-free
interval (Figure 2).
In synchronous tumours, disease must be stabilized with chemotherapy. To consider surgery,
there should not be extrahepatic disease or it must be a solitary bone metastasis. Surgery can
be technically hampered because of the effects of chemotherapy on liver parenchyma. Hillar
lymphadenectomy can be considered since positive lymph nodes are frequent, although they
do not exclude resection.
Liver recurrence is very high but the best chemotherapy regimen in these cases is to be defined.
Survival after resection is longer compared with other treatments, although disease-free time
is usually brief.
Other studies suggest that liver resection in highly selected patients may function as a
cytoreductive rather than a curative procedure, because breast liver metastases is considered
as a disseminated disease, but as a cytoreductive approach it improves the survival rate.
 
Figure 2. years old woman with alone liver metastases that involved two hepatic veins. We removed Sg 2,3,4,5,and 8.
She is disease-free 5 years after liver resection.
3.2.3. Liver metastases from melanoma
Up to 30% of patients with melanoma develop distant metastases. After the luns and brain,
the liver is the third most involved organ. Previously considered an infrequent condition,
Liver Tumors - Epidemiology, Diagnosis, Prevention and Treatment156
autopsy studies have shown liver metastases in 55%-75% of the patients with melanoma
[148,149]. Diagnosis is generally made by imaging studies during follow-up, since symptoms
are suggestive of advanced disease. FDG PET/CT shows a sensitivity of 85%, a specificity of
100% and a positive predictive value of 98% [150]. Median survival in these patients ranges
between 2 and 6 months [151]. Palliative radiotherapy and systemic chemotherapy do not
prolong survival and, although interferon-α and interleukin-2 have yielded promising
response rates, these are rarely durable [152].
Liver resection achieves 5-year survival rate between 5% and 25% [153] (Table 6). A reduction
in immunosuppressive factors and a slowing of the growth of occult metastases have been
proposed as part of the beneficial effects of surgery [154]. A large series reports a 21% 5-year
survival rate for 104 patients after resection of liver metastases from melanoma of choroidal
origin and a 22% 5-year survival rate for 44 patients with the same condition but with a
cutaneous source [114]. The same paper confirmed that choroid melanomas were commonly
associated with multiple intrahepatic tumours but were less likely than cutaneous melanomas
to be associated with extrahepatic disease. A series collected from four centres showed that
the location of the primary tumour substantially impacts on the recurrence and survival after
resection of secondary liver tumours. Among 40 patients who underwent liver resection, the
rate of recurrent hepatic metastases was higher among patients with ocular (53.3%) compared
to those with cutaneous tumours (17.4%) [148].
Authors Year n 5-year survival (%) Median survival (months)
Ripley et al. [155] 2010 35 53 -
Rose et al. [149] 2001 24 29 28
Pawlik et al. [148] 2006 24 47.2(2years) 23.6
Chua et al. [153] 2010 13 40 (3years) 21
Herman et al. [156] 2007 10 - 22
Crook et al. [157] 2006 5 - -
Table 6. Liver resection in melanoma
Positive prognostic factors are a R0 resection, a solitary metastasis and absence of extrahepatic
disease [155]. Resection with negative margins offers the only chance of long-term survival,
since for R1 and R2 resection there are not periods of survival longer than 6 months.
For all the authors, liver resection must not be considered as a curative treatment but as a part
of the whole oncologic treatment because of its cytoreductive nature. Reported series during
the last decade show that liver resection of metastases from melanoma are infrequent, that the
interval between treatment of primary and secondary tumour is long (49 to 96 months), that
mayor hepatectomies are performed in 50% to 60% of the patients and that survival varies
widely (0% to 53%), which indicates that this is a very heterogeneous group of patients with
a very variable criteria for resection.
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3.2.4. Liver metastases from gastric cancer and others non-colorectal gastrointestinal adenocarcinoma
Many reports defend liver resection for metastatic gastric cancer although the indications for
resection have not been established. Frequently, liver metastases suggest an advance disease
with a mean survival of less than 6 month. Last studies showed increased survival benefit with
5-year survivors between 20%-42%.
Positive pronostic factors have been indentified: solitary tumour or no more than 3 nodules,
size less than 5 cm, unilobular distribution, resection margin more than 10 mm and disease-
free interval between gastric cancer resection and liver metastases longer than 1 year [158]. In
a study by Thelen the multivariate analysis revealed only resection margin as an independent
prognostic factor for survival [159]. Shirabe concluded that synchronous hepatectomy should
not be a contraindication for hepatic resection [160] (Table 7).
Authors Year n 5-year survival (%)
Ambiru et al. [161] 2001 40 15
Zacherl et al. [162] 2002 15 0
Saiura et al. [163] 2002 10 20
Okano et al. [164] 2002 19 21
Shirabe et al. [160] 2003 36 11
Sakamoto et al. [158] 2003 26 4
Roh et al. [165] 2005 11 18
Summary 157 12,1
Table 7. long-term of liver resection in gastric cancer
In conclusion, the results of liver resection in liver gastric metastases should not be dismissed
simply because there is not prospective, randomized data. For patients with hepatic disease
amenable to surgical resection, treatment alternatives include systemic chemotherapy,
locoregional ablative therapies with or without systemic treatment or surgical resection with
or without systemic treatment. It is not unreasonable to consider liver resections in highly
selected patients as part of multidisciplinary care for this malignancy.
For other non-colorectal gastrointestinal adenocarcinoma the available evidence for hepatec‐
tomy is extremely limited, and this treatment strategy lacks utility. Most authors, despite
having performed hepatectomies for these metastatic tumours, agree that it is associated with
a poor prognosis.
3.2.5. Liver metastases from lung cancer
We can re-emphasize that the refinements in perioperative care and surgical techniques have
significantly improved the safety of liver surgery, and operative mortality has decreased to
around 1% in tertiary referring centres. For this, in the last 10 years liver resection has been
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proposed not only for colorectal and neuroendocrine metastases, but also for metastatic
tumour from other sites such as lung cancer.
Liver resection for lung cancer metastases are rare and few number of cases are reported in
the literature. The reported cases appear frequently with other kind of metastastic liver tumour
in more large series. Lindlell et al., in the largest serie, reported three cases but did not show
the outcome [166]. Di Carlo reported a case of long-term survival [167].
In summary,  when a  patient  has  one or  two liver  nodules  with more than one year  of
disease-free  interval  from  the  resection  of  primary  tumour,  hepatic  resection  can  be  a
therapeutic  option  [168].  Liver  involvement  is  managed  surgically  only  under  these
exceptional circumstances.
3.2.6. Liver metastases from ovarian and testicular cancer
Epithelial ovarian cancer is a highly chemosensitive disease, and platinum-based therapies
bring about significant diminution of tumour volume in most of the patients. Regrettably, the
patients develop resistance to platinum chemotherapy after 24-36 months. Notwithstanding,
many centres, despite stage III-IV advanced ovarian cancer, with a median survival of 3.5 years,
propose very aggressive management with surgical debulking [169]. Five-years disease-
specific survival after hepatic resection in patients with hepatic metastases from NCRNNE
carcinoma is comparable to the 5-year survival of patients after hepatic resection for colorectal
cancer, ranging from 9% to 38%, depending on the type of primary tumour. For this, multiple
studies have shown an important survival benefit when primary cytoreductive surgery
precedes the initiation of chemotherapy for advanced ovarian cancer. The benefits of cytore‐
ductive surgery are also obvious in patients with recurrent disease. More than 70% of patients
with advanced stage disease suffer recurrence and the benefits of second debulking depend
on chemosensitivity, feasibility of surgery and tumour behaviour.
The liver is rarely the only site of metastatic ovarian cancer but also hepatectomy can be
important  in  a  cytoreduction  approach.  Ovarian  cancer  can  involve  the  liver  through
peritoneal lesions on the surface or with intraparenchymal metastases [170]. Survival is clearly
improved  for  stage  IV  disease  patients  with  complete  and  adequate  debulking,  even
hepatectomy.
In conclusion, hepatic metastases should not preclude attempts at optimal secondary cytore‐
ductive surgery. When cytoreductive resection is performed by pelvic and hepatobiliary
surgeons, morbidity and mortality appear no different from that attributed to aggressive
surgical debulking istself.
Metastasectomy is wel established in the management of disseminated non-seminomatous
germ cell testicular carcinoma that does not completely respond to chemotherapy. Testicular
cancer has often been described as ‘the model of a curable cancer’. Previously to the mid-1970s
treatment cured less than 5% of patients; by 1984, the cure rate for testicular cancer was higher
80% and experimental protocols began to focus on the refractory cases or ‘poor risk’ patients.
The key to success in the treatment of metastatic germ cell tumours is due to the multidisci‐
plinary approach. Although after chemotherapy it can be difficult to differentiate active
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residual tumour from necrosis or fibrosis, the probability of achieving cure by surgical
resection is high. For these reasons, lymphadenectomy and visceral resection are recommend‐
ed if there is imaging evidence of residual disease [171]. In some cases complete excision
requires multivisceral radical resections as a last attempt to cure patients who have exhausted
all other therapeutic options. Complete surgical resection of all measurable disease is the gold
standard and correlates with improvement in both relapse-free and overall survival after
hepatectomy, with actuarial survival rates of 78% at 3 years in these tumours.
3.2.7. Renal cell carcinoma and urothelial cancer
The available data on hepatic resection for renal cell cancer (RCC) metastases and urothelial
cancer (UC) are limited to case reports. In metastatic RCC, the liver involvement is present in
20% of the patients and carries less than 10% of overall 1-year survival rate. Furthermore, only
5% of metastatic RCC patients have the liver as only involved organ. However, five-year
survival of 33% has been reported following resection of lung, brain or lymph node metastases
in association with chemotherapy in UC. Furthermore, metastasectomy has been used for
palliation with good results [171]. However Alves et al. reported 46 liver resection for meta‐
static RCC patients with a 5-year survival of 13% [172].
These limited data determine inconsistent recommendations for hepatectomy in metastatic
RCC and UC. In RCC, the use of sunitinib or surafenib as neoadjuvant or post-hepatectmy
therapy could improve the outcome.
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